CRISPR Therapeutics
VC Fund
Cambridge, United States
CRISPR Therapeutics is a VC fund in Cambridge focused on Biotechnology. CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from theirscientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries CRISPR Therapeutics invests in
Stages CRISPR Therapeutics invests in
Countries CRISPR Therapeutics invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Julianne Bruno
Chief Operating Officer
|
Chief Operating Officer | Total investments: 1 | Find email | |
|
Andrew Kernytsky
Senior Director, Head of Genomics and Computational Biology
|
Senior Director, Head of Genomics and Computational Biology | Total investments: 0 | Find email | |
Chris Gemmiti
Executive Director of Technical Operations
|
Executive Director of Technical Operations | Total investments: 0 | Find email | |
Craig Mello
Scientific Founders
|
Scientific Founders | Total investments: 0 | Find email | |
Daniel Anderson
Scientific Founders
|
Scientific Founders | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells. | $85M / Series A / Jun 25, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does CRISPR Therapeutics invest in?
CRISPR Therapeutics invests primarily in Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CRISPR Therapeutics?
Public channels for CRISPR Therapeutics include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CRISPR Therapeutics?
The team at CRISPR Therapeutics includes Julianne Bruno (Chief Operating Officer), Andrew Kernytsky (Senior Director, Head of Genomics and Computational Biology) and Chris Gemmiti (Executive Director of Technical Operations), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
